NON-SMALL CELL LUNG CANCER (NSCLC)
Clinical trials for NON-SMALL CELL LUNG CANCER (NSCLC) explained in plain language.
Never miss a new study
Get alerted when new NON-SMALL CELL LUNG CANCER (NSCLC) trials appear
Sign up with your email to follow new studies for NON-SMALL CELL LUNG CANCER (NSCLC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Drug duo aimed to shrink tumors before lung cancer surgery
Disease control TerminatedThis study tested whether giving two immunotherapy drugs (tiragolumab and atezolizumab), with or without standard chemotherapy, before and after surgery could help people with early-stage, operable lung cancer. The goal was to see if this approach was safe, could shrink tumors be…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 03, 2026 21:41 UTC
-
First human test of new pill targets 'Undruggable' cancer mutation
Disease control TerminatedThis early-stage study tested a new oral drug, AZD0022, alone and combined with another cancer drug, in people with advanced solid tumors driven by a specific genetic change called KRASG12D. The main goals were to find a safe dose and see if the treatment caused any side effects.…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New immune therapy tested for Tough-to-Treat cancers
Disease control TerminatedThis early-stage study tested a new drug called TAK-186 in adults with advanced cancers of the head & neck, lung, or colon that could not be removed by surgery. The main goal was to find a safe dose and understand the drug's side effects. Researchers also looked for early signs t…
Matched conditions: NON-SMALL CELL LUNG CANCER (NSCLC)
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC